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1. Introduction 
Insulin secretion from the pancreatic &cell is known 
to be an energy-dependent process and can be inhibited 
by agents uch as 2,4dinitrophenol which block 
mitochondrial ATP production [l]. Despite this fact, 
the properties of islet mitochondria have not been 
studied in detail and little is known about islet mito- 
chondrial bioenergetics. 
The exchange of ADP and ATP between cytosol 
and mitochondrial matrix is generally accepted to be 
the rate-limiting step in the regulation of oxidative 
phosphorylation [2]. This exchange iscatalysed by 
the adenine nucleotide translocase (ANT) which is 
located in the inner mitochondrial membrane. Employ- 
ing specific inhibitors including atractylate, bongkrekic 
acid and long-chain fatty acyl CoA esters, that ANT 
has been extensively investigated inheart and liver 
mitochondria [3-51. This communication represents 
the first report of the existence of an active ANT in 
islet mitochondria nd characterizes the carrier in 
terms of its sensitivity to specific inhibitors. In addi- 
tion, the effects of these inhibitors upon rates of islet 
glucose metabolism to COz and of glucose-stimulated 
insulin secretion are reported. 
2. Experimental 
2.1. Materials 
Collagenase (type V, 320 units/mg) and atractylate 
Direct correspondence to: Dr Robin Ewart, Diabetes Program, 
University ofWisconsin-Madison, H4/566, Center for Health 
Sciences, 600 North Highland Avenue, Madison, WI 53792, 
USA 
were obtained from Sigma and carboxyatractylate 
from Boehringer. [“Cl AMP, [ r4C] ADP and [ 14C]- 
ATP were from New England Nuclear and [U-‘4C]- 
glucose and insulin assay kits from Amen&am. 
Unlabelled ADP, ATP and palmitoyl-CoA were from 
PL Biochemicals (Milwaukee WI). Bongkrekic acid 
was the kind gift of Dr Berends (Delft University of 
Technology). Other reagents were of the highest 
purity available commercially. 
2.2. Isolation and incubation of islets 
Islets were isolated from the pancreas of male 
SpragusDawley rats (250 g) by collagenase digestion 
[6]. Bates of islet insulin release and of islet glucose 
metabolism were determined as in [7]. 
2.3. Preparation of islet subcellular fractions 
Islets were homogenized at 4°C in medium con- 
taining 210 mM marmitol, 70 mM sucrose, 10 mM 
Tris-HCl and 1 mM EDTA (pH 7.4) using a 2 ml 
ground-glass homogenizer. Subcellular f actions were 
then isolated by differential centrifugation as in [8]. 
Submitochondrial particles were prepared as in [9] 
except hat 5 mM ADP was substituted for ATP in 
the sonication medium. Protein concentrations were 
determined as in [lo]. 
2.4. Assay of adenine nucleotide translocase and 
cytochrome oxidase 
Cytochrome oxidase activity was measured in sub- 
cellular fractions pectrophotometrically at 550 nm 
as in [l 11. ANT activity was measured at 4°C using 
the forward exchange method [ 121 with slight modi- 
fication [ 131. Unless otherwise stated, all the experi- 
ments reported were carried out at least 3 separate 
times. 
Published by Elsevier Biomedical Press 
00145793/S2/0000-0000/$02.75 0 1982 Federation f European Biomedical Societies 205 
Volume 137, number 2 FEBS LETTERS 
Table 1 
Distribution of cytochrome oxidase and adenine nucleotide translocase activities in 
subcellular fractions of rat pancreatic islets 
Fractions Cytochrome oxidase 
(nmol . min-' . mg protein-‘) 
Adenine nucleotide 
translocase activity 
(nmol . mm-r . mg protein-‘) 
Homogenate n.d. 0.021 
Nuclei + cell debris 0.072 - 
Mitochondria 0.273 0.019 
Secretory granules 0.105 - 
January 1982 
n.d., not determined 
Cytochrome oxidase and adenine nucleotide translocase activities were determined as in 
section 2. The values represent an average of 2 expt 
3. Results and discussion 
Table 1 compares the distribution of ANT and 
cytochrome oxidase in the subcellular f actions 
obtained from the differential centrifugation of the 
islet homogenate. As shown, the mitochondrial frac- 
tion represented -90% of the ANT and 60% of the 
cytochrome oxidase nzyme activity. Uptake of 
[ r4C] ADP was linearly related to the concentration 
of mitochondrial protein over the range tested (fig.1). 
The demonstrated lack of penetration of [ r4C]AMP 
under identical conditions upports the presence of a 
specific translocase for ADP and ATP in the islet 
mitochondria (fig.1). 
It has been well documented [3,5,13,14] that 
atractylate, bongkrekic acid and long-chain acyl CoA 
esters inhibit the transport of adenine nucleotides 
4r -I 
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Fig.1. Adenine nucleotide translocase in islet mitochondria. 
The activity was measured by the forward exchange method 
and stopped by rapid fdtration [ 12,131. Each point is an 
average of 3 expt. 
across the inner membrane of mitochondria isolated 
from heart and liver. It was therefore of importance 
to investigate the effects of these inhibitors upon 
[ 14C] ADP uptake by islet mitochondria. Fig.2 shows 
the sensitivity of the islet ANT to inhibition by 
atractylate, bongkrekic acid and palmitoyl CoA. 
From fig.2, it is apparent that the islet mitochondrial 
translocase was inhibitable by these agents although 
the sensitivity of the carrier appeared to be somewhat 
less than is the case with that of heart and liver mito- 
chondria. With increase in the concentrations of the 
inhibitors, however, qualitatively similar, dose-related 
inhibition of [ 14C] ADP transport was observed with 
all 3 agents (fig.2A). Thus, -75% inhibition of [ i4C]- 
ADP transport was seen in the presence of lo-’ M 
atractylate or palmitoyl-CoA and of 1 Oa M bongkrekic 
acid. Since atractylate acts to inhibit the ANT only at 
the outer surface of the inner mitochondrial mem- 
brane, the effect of this inhibitor was next examined 
employing mitochondria pre-inverted by sonication. 
The expected abolition of the atractylate ffect con- 
firmed in this experiment ( ig.2B) further supports 
the conclusion that the [ 14C] ADP transport observed 
is a function of an islet mitochondrial ANT. By con- 
trast, the inhibitory effects of bongkrekic acid and 
palmitoyl-CoA were essentially unaltered when these 
agents were tested using inverted submitochondrial 
particles (fig.2B). 
An alternative mechanism of adenine nucleotide 
transport has been described in liver mitochondria 
from perinatal rats [ 15,161. This so-called Mg2+- 
dependent, atractylate-independent uniport system 
does not appear to be present in Islet mitochondria 
since, in the presence of atractylate, no stimulatory 
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Fig.2. Sensitivity of adenine nucleotide translocase to inhibi- 
tion by increasing concentrations of atractylate (e-o), 
palmitoylCoA (u-u), and bongkrekic acid (o---o) in 
rat islet mitochondria [A] and submitochondrial particles 
[B]. The indicated amounts of each inhibitor were added to 
an incubation mixture of total volume 0.5 ml. Each point is 
an average of 3 expt. 
effect of Mg2+ upon ATP uptake by adenine nucleo- 
tide-depleted islet mitochondria was seen (fig.3). 
Finally, the effects of inhibitors of ANT were 
investigated in intact islets. Atractylate and its car- 
boxy derivative at 1.2 X lOa M were both without 
effect upon rates of islet insulin release or glucose 
metabolism (table 2). By contrast, bongkrekic acid at 
2 X 1 O-’ and 2 X 1 OA M led to significant inhibitions 
1.0 _- 
0.5 /I E 
0 
Td5hi”) 
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Fig.3. Assay for a functional adenine nucleotide uniport sys- 
tem in islet mitochondria. The experiment was done as in 
[ 151. Mitochondria were depleted of adenine nucleotides by 
treatment with pyrophosphate. The depleted mitochondria 
(0.01-0.05 mg protein) were then incubated with 0.1 mM 
[ r4C] ATP in the presence of 10m5 M atractylate in the 
presence (e-e) or absence (A---A) of 10 mM MgCl, and 
ATP uptake was determined as in [ 151. At the times indicated 
the suspension was ffltered through miBipore filters, and 
rapidly washed with 10 ml 150 mM NaCl. Radioactivity on 
falters was determined by liquid scintillation counthrg. 
of both glucose-stimulated insulin release and, at the 
higher concentration, ofmetabolism of [U-r4C]glucose 
to 14C02 (table 2). In light of the inhibitory effects 
seen with bongkrekic acid, it seems likely that the 
failure of effect of atractylate and carboxyatractylate 
is attributable to poor penetration of these agents 
across the islet cell membranes as has been reported 
for intact heart tissue [ 171. In table 2, the effects of 
2,4dinitrophenol(2 X lo4 M) upon the rate of 
insulin release and of iodoacetamide (5 X lo4 M) 
upon rates of glucose metabolism are included as 
positive controls. 
We have demonstrated the presence in islet mito- 
chondria of an adenine nucleotide translocase which 
exhibits ensitivity to inhibitors similar to that 
observed in mitochondria from other tissues. In the 
intact islet, bongkrekic acid in the concentration range 
shown to inhibit the translocase of isolated mitochon- 
dria, was shown to inhibit glucose-stimulated insulin 
release. Since phosphoenolpyruvate, which is known 
to be transported by the ANT in other tissues [18, 
191, has been suggested asa possible ‘signal’ for glucose- 
stimulated insulin release by inducing Ca2* egress 
from the mitochondria [20,21], we are now investi- 
gating the possible significance of these findings in 
relation to stimulus-secretion coupling in the islets. 
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Table 2 
January 1982 
Effects of inhibitors on rates of islet insulin release and glucose metabolism 
Additions to medium Rate of insulin secretion Rate of [U-W]glucose 
(pI_l .2 islets-‘. h-l) metabolism to i4C0 2 
(pmol . 5 islets-’ . h-i) 
Glucose concentrations in medium 
2mM 20 mM 
Control 13 * 1 (6) 238 f 19 (10) 70 * 4 (8) 
Atractylate (1.2 X lo4 M) 14 f 4 (6) 254 f 25 (12) 64 f 6 (8) 
Control 12 i 2 (6) 150 f 11 (10) 70 f 4 (8) 
Carboxyatractylate (1.2 X lo4 M) 9 * 1 (6) 173 f 14 (10) 77 ? 7 (8) 
Control 14 * 4 (6) 232 f 28 (8) 109 f 6 (12) 
Bongkrekic acid (2 X lo-’ M) - 134 f 22 (1o)a - 
Bongkrekic acid (2 X lo4 M) 18 f l(6) 50 f 8 (lO)b 60 + 5 (12)b 
2,4-Dinitrophenol (2 X lo4 M) - 12 f 10 (4)b - 
Iodoacetamide (5 X lo4 M) - 15 f 2 (8)b 
- 
a p < 0.02 vs corresponding control; b p < 0.001 vs corresponding control 
Rates of islet insulin release and glucose metabolism were determined as in section 2. Results are 
expressed as means * SEM for (no. obs.) 
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